- Home
- AMAL vs CDNA Comparison
AMAL vs CDNA Comparison
Compare AMAL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | CDNA |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AMAL | CDNA |
|---|---|---|
| Price | $37.64 | $17.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $36.00 | $27.33 |
| AVG Volume (30 Days) | 128.7K | ★ 512.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $21.18 | $15.37 |
| Revenue Next Year | $6.55 | $11.23 |
| P/E Ratio | $11.02 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $25.13 | $10.96 |
| 52 Week High | $42.66 | $21.49 |
Technical Indicators
Market Signals| Indicator | AMAL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 43.44 |
| Support Level | $36.59 | $16.74 |
| Resistance Level | $39.34 | $18.02 |
| Average True Range (ATR) | 1.25 | 0.70 |
| MACD | -0.24 | -0.09 |
| Stochastic Oscillator | 22.92 | 44.44 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.